1-8 of 8
eculizumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome

Clinical Trials & Observations
Shruti Chaturvedi, Noor Dhaliwal, Sarah Hussain, Kathryn Dane, Harshvardhan Upreti, Evan M. Braunstein, Xuan Yuan, C. John Sperati, Alison R. Moliterno, Robert A. Brodsky
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1504–1512.
https://doi.org/10.1182/bloodadvances.2020003175
Published: 2021
Journal Articles

Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients

Clinical Trials & Observations
Jeroen D. Langereis, Bryan van den Broek, Sjoerd Franssen, Irma Joosten, Nicole M. A. Blijlevens, Marien I. de Jonge, Saskia Langemeijer
Journal: Blood Advances
Blood Adv (2020) 4 (15): 3615–3620.
https://doi.org/10.1182/bloodadvances.2020002497
Published: 2020
Journal Articles

Interferon-complement loop in transplant-associated thrombotic microangiopathy

Clinical Trials & Observations
Sonata Jodele, Mario Medvedovic, Nathan Luebbering, Jenny Chen, Christopher E. Dandoy, Benjamin L. Laskin, Stella M. Davies
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1166–1177.
https://doi.org/10.1182/bloodadvances.2020001515
Published: 2020
Includes: Supplemental data
Journal Articles

Paroxysmal cold hemoglobinuria successfully treated with complement inhibition

Clinical Trials & Observations
Sarah A. Lau-Braunhut, Hannah Stone, Griffin Collins, Sigbjørn Berentsen, Benjamin S. Braun, Matt S. Zinter
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3575–3578.
https://doi.org/10.1182/bloodadvances.2019000897
Published: 2019
Journal Articles

Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion

Clinical Trials & Observations
Andrew Jay Portuguese, Brea Lipe
Journal: Blood Advances
Blood Adv (2018) 2 (23): 3443–3446.
https://doi.org/10.1182/bloodadvances.2018027532
Published: 2018
Journal Articles

Eculizumab in cold agglutinin disease (DECADE): an open-label, prospective, bicentric, nonrandomized phase 2 trial

Clinical Trials & Observations
Alexander Röth, Martin Bommer, Andreas Hüttmann, Dörte Herich-Terhürne, Nils Kuklik, Jan Rekowski, Veronika Lenz, Hubert Schrezenmeier, Ulrich Dührsen
Journal: Blood Advances
Blood Adv (2018) 2 (19): 2543–2549.
https://doi.org/10.1182/bloodadvances.2018024190
Published: 2018
Journal Articles

Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies

Clinical Trials & Observations
Alexander Röth, Scott T. Rottinghaus, Anita Hill, Eric S. Bachman, Jin Seok Kim, Hubert Schrezenmeier, Louis Terriou, Álvaro Urbano-Ispizua, Richard A. Wells, Jun Ho Jang, Austin G. Kulasekararaj, Jeff Szer, Rasha Aguzzi, Andrew I. Damokosh, Lori Shafner, Jong Wook Lee
Journal: Blood Advances
Blood Adv (2018) 2 (17): 2176–2185.
https://doi.org/10.1182/bloodadvances.2018020644
Published: 2018
Includes: Supplemental data
Journal Articles

Use of the complement inhibitor Coversin to treat HSCT-associated TMA

Clinical Trials & Observations
Timothy H. J. Goodship, Fernando Pinto, Wynn H. Weston-Davies, Juliana Silva, Jun-ichi Nishimura, Miles A. Nunn, Ian Mackie, Samuel J. Machin, Liina Palm, Jeremy W. Pryce, Robert Chiesa, Persis Amrolia, Paul Veys
Journal: Blood Advances
Blood Adv (2017) 1 (16): 1254–1258.
https://doi.org/10.1182/bloodadvances.2016002832
Published: 2017
Includes: Supplemental data